Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...
Show Filters
White Paper
This white paper outlines four best practices to increase probability of success: 1) Understanding patient motivators at each stage of the diabetes journey; 2) Designing the protocol and informed consent form to be patient-centered and “fit for purpose;” 3) Setting expectations for 100% retention; and 4) Using “site intelligence” to provide sites with preferred recruitment and retention tools. Authors: Erica Caveney, M.D., Vice President and Head, Diabetes Center of Excellence, Quintiles Tracy Stewart, MBA, Director, Global Biosimilars Unit, Quintiles Scott Oakes, Ph.D., Director, Clinical Project Management, Quintiles Kimberly Powers, Sr. Client Engagement Manager, Health Engagement & Communications,...
Explore More
White Paper
This white paper describes new approaches to developing more effective and sustainable therapies for RA and innovative ways to conduct RA clinical trials more efficiently, successfully demonstrating value to patients and key stakeholders.  Authors: Iain B. McInnes, PhD, FRSE, FMedSci, Muirhead Professor of Medicine and Director of the Institute of Infection, Immunity and Inflammation, University of Glasgow, Scotland Mary Katherine (MK) Farmer, MD, Therapeutic Strategy Lead, Rheumatology, Senior Medical Director, Immunology and Internal Medicine Therapeutic Delivery Unit, Quintiles Andrew Platt, PhD, Scientific Advisor, Global Central Laboratories,...
Explore More
White Paper
The year 2015 marks the 10th anniversary of the release of two ICH Harmonised Tripartite Guidelines that have governed the cardiac safety regulatory landscape, more specifically the proarrhythmic cardiac safety landscape, since their release in May 2005. ICH S7B addresses the non-clinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals, and ICH E14 addresses the clinical evaluation of QT interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, with a focus on the Thorough QT (TQT) Study. Our discussions in this paper focus on clinical evaluations. Authors: Snehal Kothari, MD, DM, FACC, FESC Dilip R. Karnad, MD, FACP, FRCP Gopi Krishna Panicker, BHMS, PGDCR J. Rick Turner,...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – February 25, 2015 – Quintiles announced today that it has been named to the 2015 CSO50 by IDG's CSO magazine in recognition of the company’s risk mitigation strategy managing Windows XP security challenges. CSO commended the Quintiles team for its innovative defense-in-depth model which minimized security risks for business-critical applications dependent on Windows XP, delivering secure and segmented platforms while protecting critical company assets. “This was an innovative solution to a problem that presents significant security concerns for many organizations around the world,” said Quintiles Chief Information Security Officer Patricia Collins Weedon. “Quintiles has launched many innovative customer solutions that require our team to think beyond current...
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – February 24, 2015 – Quintiles today announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles’ Advisory Services organization and the continued development and delivery of its related services. Bringing more than 25 years of experience to Quintiles, Elgar joins Quintiles from Bain & Company, a global business consulting firm, where he was a senior partner in its Global Healthcare Practice Group and a leading client service partner. Prior to Bain, Elgar spent more than a decade at McKinsey and Company in various leadership roles. “Throughout his career, Elgar has focused on the healthcare industry, providing cutting-edge insight and guidance in boardrooms of...
Read More
Scientific Poster
> read the full article that appeared in the Journal for Clinical...
Explore More
White Paper
Part two our three-part Executive Vision Forum White Paper discusses how biopharma can achieve innovations in medicine and remain competitive by preventing disease as opposed to reacting to it. This requires a proactive healthcare model - new technology, changes in the way we communicate with patients, and new structures to measure value and compensate physicians and pharma for the prevention solutions they...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – February 19, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for 2015. Quintiles is ranked third overall in FORTUNE’s Healthcare: Pharmacy and Other Services category with the top ranking for the reputation attribute of “global competitiveness” and second within the segment for its “people management.” FORTUNE's World's Most Admired Companies list is the definitive report card on corporate reputations. Since 1997, Fortune has identified, selected and ranked the World’s Most Admired Companies, uncovering the business practices that make these companies highly regarded among their peers. “I would like to congratulate Quintiles’ employees around the world for...
Read More
Fact Sheet
Genomics technology is transforming oncology treatment and drug development. The tools are now available to better understand the relationship between biomarkers and patient responses. Quintiles has developed the Quintiles Comprehensive Cancer Panel (QCCP), a targeted sequencing assay for analysis of genomic variation correlated with response to available therapeutics and with response to marketed and experimental therapies in clinical...
Read More
Scientific Poster
> read the abstract at International Pharmaceutical...
Explore More
Fact Sheet
Clinical research into new rheumatoid arthritis treatments has led to substantial progress; however, significant unmet needs still remain. See how Quintiles’ combination of therapeutic expertise, innovative processes and operational experience can help you take your RA compound all the way from lab to market. Ready to get...
Read more